About

About NanoCoeur

The story behind the name — and the operator carrying it forward across the life sciences product development lifecycle.

Dr. John Fontana and Ihab Rashad with the Chancellor of UMass Lowell Ihab Rashad with Nikki Tsongas and Mark Biden, Sr. Research Fellow at Boston Scientific

In memory of Dr. John Fontana

Why NanoCoeur

Built on a Legacy. Committed to the Mission.

Fresh out of my MBA, I joined my first startup, NanoCoeur Inc., alongside its founder, Dr. John Fontana. It was one of the luckiest breaks of my career. John wasn't just a boss — he became a mentor who stayed by my side for years, celebrating everything from my graduation to my wedding.

Two years ago, I spoke with him after his surgery. As I tried to cheer him up by asking about our next big startup idea, he said something I'd never heard him say before: "I don't know, not this time…" A few months later, he was gone. Because I never got that final visit he asked for, I felt a lack of closure — like something had been left unfinished.

Before he passed, John handed me the reins — wanting to ensure the spirit of the idea lived on. Choosing to name this firm NanoCoeur was a deeply personal decision. This name represents more than a business; it is a commitment to the same innovation and grit I witnessed with John fifteen years ago.

NanoCoeur Consulting brings that agile, entrepreneurial spirit to organizations seeking strategic operations expertise across the life sciences product development lifecycle.

Ihab Rashad — Founder, NanoCoeur Consulting
Founder

Ihab Rashad, MBA, PMP

Life Sciences Program Management Consultant · Fractional PMO · Serving clients nationwide

Life sciences program management consultant with 15+ years advancing drug development, medical device, and IVD programs from early R&D through commercialization. Across oncology, orthopedics, diagnostics, and blood products, Ihab has established more than half a dozen PMOs from the ground up, secured FDA IND approvals, led partnerships with global diagnostics and device organizations, and directed cross-functional teams globally — supporting programs that have collectively garnered $100M+ in funding.

His fractional PMO engagements have delivered measurable outcomes in funding readiness, operational efficiency, and regulatory performance for clients ranging from early-stage biotech startups to publicly traded life sciences companies — with active AI integration work spanning governance, workflow automation, and executive decision enablement.

Start a conversation →